Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two most prescribed GLP-1-based medications for type 2 diabetes, and both produce significant weight loss. But they work differently, and the clinical data shows meaningful differences in outcomes.
This comparison breaks down the head-to-head data, mechanism differences, cost, side effects, and practical considerations to help you and your doctor make the right choice.
Ozempic vs Mounjaro at a Glance
| Feature | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA approvals | Type 2 diabetes, CV risk reduction | Type 2 diabetes |
| Frequency | Once weekly (injection) | Once weekly (injection) |
| Doses available | 0.25, 0.5, 1, 2 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Avg. A1C reduction | 1.2–1.8% | 1.9–2.5% |
| Avg. weight loss (diabetes) | 12–14 lbs | 15–25 lbs |
| Retail cost (no insurance) | ~$900–1,000/month | ~$1,000–1,100/month |
| CV outcomes data | Yes (SUSTAIN 6: 26% MACE reduction) | Pending (SURPASS-CVOT ongoing) |
| Weight-loss formulation | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide) |
| Available since | 2017 | 2022 |
How They Work Differently
This is the fundamental distinction between the two drugs, and it likely explains the differences in clinical outcomes.
Ozempic: Single GLP-1 Agonist
Semaglutide activates the GLP-1 receptor only. This single-pathway approach stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through brain signaling. It is a proven, well-understood mechanism backed by decades of GLP-1 research.
Mounjaro: Dual GIP/GLP-1 Agonist
Tirzepatide is the first approved dual incretin agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone that:
- Enhances insulin secretion through a pathway complementary to GLP-1
- May improve fat tissue metabolism and insulin sensitivity
- Appears to have independent effects on appetite and weight regulation
- May enhance the GLP-1 pathway's effects through receptor cross-talk
The dual mechanism creates a "1 + 1 = 3" effect — the combination of GIP and GLP-1 agonism appears to produce greater metabolic improvements than either pathway alone. This is the leading hypothesis for why Mounjaro shows superior weight loss and A1C reduction in clinical trials.
Why GIP Matters
Interestingly, GIP was initially studied as an antagonist (blocker) for obesity treatment. The discovery that GIP agonism — when combined with GLP-1 agonism — produces greater weight loss was unexpected and represents a paradigm shift in metabolic pharmacology.
Head-to-Head Comparison: What the Trials Show
Weight Loss
While there's limited direct head-to-head trial data, cross-trial comparisons and the SURPASS-2 study (which compared tirzepatide to semaglutide 1 mg) provide clear signals:
| Study | Drug / Dose | Avg. Weight Loss | Duration |
|---|---|---|---|
| SUSTAIN 7 | Semaglutide 0.5 mg | 9.3 lbs (4.3 kg) | 40 weeks |
| SUSTAIN 7 | Semaglutide 1 mg | 13.0 lbs (5.9 kg) | 40 weeks |
| SURPASS-2 | Semaglutide 1 mg (comparator) | 12.5 lbs (5.7 kg) | 40 weeks |
| SURPASS-2 | Tirzepatide 5 mg | 16.5 lbs (7.6 kg) | 40 weeks |
| SURPASS-2 | Tirzepatide 10 mg | 21.4 lbs (9.8 kg) | 40 weeks |
| SURPASS-2 | Tirzepatide 15 mg | 25.3 lbs (11.2 kg) | 40 weeks |
SURPASS-2 is the only head-to-head trial comparing tirzepatide directly to semaglutide 1 mg. All tirzepatide doses showed statistically superior weight loss.
A1C Reduction (Blood Sugar Control)
In SURPASS-2, tirzepatide showed superior A1C reduction compared to semaglutide 1 mg at all three doses:
- Tirzepatide 5 mg: -2.01% (vs -1.86% for semaglutide 1 mg)
- Tirzepatide 10 mg: -2.24%
- Tirzepatide 15 mg: -2.30%
The differences were statistically significant for the 10 mg and 15 mg doses but not for the 5 mg dose, suggesting that tirzepatide's advantage becomes more pronounced at higher doses.
Cardiovascular Outcomes
Ozempic has a clear advantage here — proven cardiovascular benefit. The SUSTAIN 6 trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE), and Ozempic carries an FDA-approved cardiovascular indication.
Mounjaro does not yet have cardiovascular outcomes data. The SURPASS-CVOT trial is ongoing, with results expected in 2026. Until this data is available, Ozempic remains the preferred choice for patients where cardiovascular risk reduction is a primary treatment goal.
Side Effect Comparison
| Side Effect | Ozempic | Mounjaro |
|---|---|---|
| Nausea | 15–20% | 12–18% |
| Diarrhea | 8–9% | 12–17% |
| Vomiting | 5–9% | 5–9% |
| Constipation | 3–5% | 6–8% |
| Decreased appetite | 5–9% | 5–11% |
| Injection site reactions | 0.2% | 3–5% |
| Discontinuation rate (GI) | 4–5% | 4–7% |
The overall GI side effect profiles are similar. Both cause nausea, diarrhea, and vomiting most commonly during dose escalation. Mounjaro has slightly higher rates of diarrhea, constipation, and injection site reactions. Both medications use gradual dose titration to minimize side effects.
Both carry the same FDA boxed warning for thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with MTC or MEN 2 history.
What You'll Pay
| Cost Factor | Ozempic | Mounjaro |
|---|---|---|
| Retail price (no insurance) | $900–1,000/month | $1,000–1,100/month |
| Manufacturer savings card | As low as $25/month (eligible patients) | As low as $25/month (eligible patients) |
| Medicare Part D | Covered for diabetes (varies by plan) | Covered for diabetes (varies by plan) |
| Insurance formulary position | Widely covered (preferred in many plans) | Increasingly covered (newer, less formulary placement) |
Ozempic has a slight edge in insurance coverage simply because it's been on the market longer (since 2017 vs 2022 for Mounjaro) and has more formulary placements. However, this gap is closing rapidly as payers add Mounjaro to their formularies.
For weight-loss-specific formulations, Wegovy (semaglutide) and Zepbound (tirzepatide) are similarly priced at approximately $1,300-$1,400/month without insurance.
Which Should You Choose?
Mounjaro may be better if:
- Weight loss is your primary goal (greater average weight loss in trials)
- You need maximum A1C reduction
- You've plateaued on Ozempic or another GLP-1 agonist
- Your insurance covers it equally
Ozempic may be better if:
- Cardiovascular risk reduction is a treatment priority (proven MACE reduction)
- You want a longer safety track record (on market since 2017)
- Your insurance has better coverage for Ozempic
- You prefer a medication with more dosing flexibility on the lower end
Either medication is a reasonable choice if:
- You have type 2 diabetes and need better blood sugar control
- You want a once-weekly injectable with a proven safety profile
- You're willing to manage GI side effects during dose escalation
Bottom Line
If the data were the only factor, Mounjaro's dual mechanism and superior weight loss/A1C data would make it the default choice for most patients. But in practice, insurance coverage, cardiovascular history, and individual response all matter. Many patients do well on either medication. Discuss both options with your healthcare provider.
Frequently Asked Questions
Sources
- Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519 (SURPASS-2)
- Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
- Rosenstock J, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)." Lancet. 2021;398(10295):143-155.
- FDA. "Ozempic (semaglutide) Prescribing Information." FDA Label
- FDA. "Mounjaro (tirzepatide) Prescribing Information." FDA Label
- Del Prato S, et al. "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)." Lancet. 2021;398(10313):1811-1824.